NBTX-001 is profiled in “Pharmacology and Therapeutics Journal” as one promising novel treatment candidates for anxiety-related disorders

by nobilistx | Dec 25, 2019 | Uncategorized |

Please click on this link to view the full article

Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Posttraumatic Stress Disorder

by nobilistx | Dec 6, 2019 | Uncategorized |

PORTLAND, ORE. (PRWEB) DECEMBER 06, 2019 Nobilis Therapeutics, a clinical stage biotechnology company focused on development of treatments for psychiatric and neurodegenerative disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared its...

Nobilis Therapeutics’ NBTX-001 Showed Beneficial Effects in an Animal Model of Autism

by nobilistx | Dec 3, 2019 | Uncategorized |

Study results published in The Journal of Translational Medicine PORTLAND, Ore., December 3, 2019 — Nobilis Therapeutics, Inc. announced today the results of its preclinical study assessing the effects of its NBTX-001, a xenon-based therapeutic, in an animal...

US Patent is Granted for Nobilis Therapeutics Invention On the Use of Noble Gases to Treat Complications of Pregnancy

by nobilistx | Nov 26, 2019 | Uncategorized |

PORTLAND, Ore., November 26, 2019 – Nobilis Therapeutics announced today the issuance of the patent (U.S. Patent No: 10,485,825 ) titled “Prevention of Pregnancy Complications by Noble Gas Administration.” “The impetus to filing this...

Nobilis Therapeutics published an article “Combining Xenon Inhalation With Trauma Memory Reactivation to Reduce Symptoms of Posttraumatic Stress Disorder: Case Report, Justification of Approach, and Review of the Literature” in Primary Care Companion For CNS Disorders

by nobilistx | Sep 20, 2019 | Uncategorized |

The article centers around a fascinating case report of a patient who had suffered from PTSD for 8 years and who, after receiving the course of treatment with xenon-augmented memory reconsolidation, was reported to have a complete recovery from symptoms of this...